Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Study Participants with Moderate to Severe Crohn's Disease
Résumé de l'étude
Crohn's disease (CD) is a gastrointestinal disorder that can cause chronic diarrhea with or without significant bleeding, abdominal pain, weight loss, and fever. This study examines the pharmacokinetics, efficacy, and safety of Risankizumab in children and adolescents aged 2 to < 18 years with moderate to severe active CD who are intolerant to other therapies or have responded inadequately. Risankizumab is an approved medication for adults with plaque psoriasis, psoriatic arthritis, and CD, and is being developed for the treatment of CD in pediatrics. This study consists of 3 cohorts that may participate in 3 sub-studies (SS). In cohort 1, patients aged 6 to under 18 years are enrolled. In cohort 2, patients aged 2 to under 6 years are enrolled. In cohort 3, patients aged 2 to under 18 years are enrolled. SS1 is an open-label induction phase where participants receive a weight-based induction therapy with Risankizumab. SS2 is a double-blind maintenance phase where participants are randomized to receive one of two doses of the weight-based induction therapy with Risankizumab. SS3 is an open continuation phase where participants receive Risankizumab based on their response in SS2. Approximately 110 children and adolescents with CD will be enrolled at approximately 100 study centers worldwide.
(BASEC)
Intervention étudiée
Participants in SS1 receive Risankizumab intravenously during the 12-week induction phase. Participants in SS2 receive Risankizumab subcutaneously during the 52-week randomized maintenance phase. Participants in SS3 receive Risankizumab subcutaneously during the 208-week open phase. Participants will be followed for approximately 140 days.
(BASEC)
Maladie en cours d'investigation
Crohn's Disease
(BASEC)
– Children and adolescents aged 2 to < 18 years – Moderate to severe active CD, defined as a PCDAI score > 30, assessed at baseline – Endoscopic evidence of mucosal inflammation, documented by an SES CD of 6 for ileocolonic or colonic disease (or an SES CD of 4 for isolated ileal disease). – Documented intolerance or inadequate response to one or more of the following drug classes: aminosalicylates, oral locally acting corticosteroids, systemic steroids (prednisone or corresponding active ingredient), IMMs and/or biologics (BASEC)
Critères d'exclusion
– Allergic reaction or significant sensitivity to any component of the investigational product (and excipients) and/or other drugs of the same class – Any of the following conditions: (a) Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD (b) CD diagnosis at age < 2 years (c) Diagnosis or suspicion of primary immunodeficiency (d) Currently known complications related to CD, including: -- Active abscess (abdominal or perianal) -- Symptomatic intestinal strictures -- > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigma, and left colon as well as rectum -- Fulminant colitis -- Toxic megacolon -- Or any other manifestations that may require surgical intervention during the study (e) Stoma or ileoanal pouch (f) Diagnosis of short bowel syndrome (g) Surgical intestinal resection within 3 months prior to baseline (except gastrointestinal surgeries that do not involve intestinal resection, such as appendectomy or stoma closure) or > 3 intestinal resections in the history (BASEC)
Lieu de l’étude
Berne, Zurich
(BASEC)
Sponsor
AbbVie Inc. North Chicago USA AbbVie AG Cham
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
AbbVie Medical Information
+41 41 399 16 89
medinfo.ch@clutterabbvie.comAbbVie AG
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale de Zurich
(BASEC)
Date d'approbation du comité d'éthique
13.02.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible